Cyrus Harmon is Director at Olema Pharmaceuticals, Inc. (OLMA). They have made 15 open-market trades across 1 company since 2021, most recently 2026-07-24.
CIK 0001831410
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 15 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| OLMA | 702,770 | $4.6M |
Shares reported on the most recent Form 4, priced at the 2026-07-27 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| OLMA | SELL | 2026-07-23 | 2026-07-27 | $11.65 | $291K | -1.0% | -9.0% | — |
| OLMA | SELL | 2026-01-20 | 2026-01-21 | $26.88 | $269K | -1.9% | -8.0% | -36.4% |
| OLMA | SELL | 2026-01-14 | 2026-01-16 | $29.12 | $102K | -0.7% | -13.8% | -37.1% |
| OLMA | SELL | 2025-12-22 | 2025-12-29 | $28.53 | $164K | +10.2% | -3.6% | -47.4% |
| OLMA | SELL | 2025-09-16 | 2025-09-18 | $8.15 | $285K | +15.0% | -8.7% | +283.1% |
| OLMA | SELL | 2024-12-10 | 2024-12-11 | $9.02 | $294K | -24.9% | -39.9% | -48.4% |
| OLMA | SELL · 10b5-1 | 2024-07-29 | 2024-07-31 | $15.58 | $141K | -24.1% | -26.6% | -26.2% |
| OLMA | SELL · 10b5-1 | 2024-07-11 | 2024-07-12 | $12.26 | $61K | +20.6% | -0.7% | -9.2% |
| OLMA | SELL · 10b5-1 | 2024-06-28 | 2024-07-02 | $10.77 | $215K | +27.0% | +59.0% | +15.4% |
| OLMA | SELL · 10b5-1 | 2024-05-31 | 2024-06-04 | $10.30 | $257K | -10.9% | -23.1% | -18.2% |
| OLMA | SELL · 10b5-1 | 2024-05-06 | 2024-05-07 | $10.92 | $55K | -10.2% | +21.3% | +26.6% |
| OLMA | SELL · 10b5-1 | 2024-04-30 | 2024-05-02 | $9.51 | $143K | -1.9% | +13.4% | +55.8% |
| OLMA | SELL · 10b5-1 | 2024-03-28 | 2024-03-29 | $10.97 | $219K | -2.8% | -9.7% | -0.4% |
| OLMA | SELL · 10b5-1 | 2024-02-29 | 2024-03-04 | $12.41 | $310K | -20.3% | -23.7% | -19.0% |
| OLMA | SELL · 10b5-1 | 2024-01-31 | 2024-02-02 | $12.79 | $384K | -1.5% | -4.7% | -34.1% |
| OLMA | SELL | 2023-12-29 | 2024-01-02 | $13.38 | $335K | -14.8% | +12.0% | -20.0% |
| OLMA | SELL · 10b5-1 | 2023-11-30 | 2023-12-01 | $12.57 | $314K | -13.0% | -6.3% | -15.4% |
| OLMA | SELL | 2023-11-21 | 2023-11-22 | $14.39 | $235K | -5.4% | +1.0% | +5.1% |
| OLMA | SELL · 10b5-1 | 2023-10-31 | 2023-11-02 | $12.65 | $379K | -0.5% | -4.4% | -18.3% |
| OLMA | SELL · 10b5-1 | 2023-09-29 | 2023-10-03 | $12.41 | $310K | +11.9% | +39.4% | +21.6% |
| OLMA | SELL · 10b5-1 | 2023-08-31 | 2023-09-05 | $10.65 | $373K | +1.7% | +0.3% | +20.3% |
| OLMA | SELL · 10b5-1 | 2023-08-16 | 2023-09-05 | $10.14 | $152K | +1.7% | +0.3% | +20.3% |
| OLMA | SELL | 2023-06-08 | 2023-06-09 | $6.30 | $63K | +3.5% | +9.1% | +42.5% |
| OLMA | SELL | 2023-06-05 | 2023-06-07 | $6.18 | $62K | +40.9% | +45.2% | +109.9% |
| OLMA | SELL · 10b5-1 | 2021-11-29 | 2021-12-01 | $24.76 | $10K | +8.9% | -1.2% | -43.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.